Patents by Inventor Chong Si
Chong Si has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12590105Abstract: The present disclosure provides compounds of the formula: where R1, R2, R3, R4, R5, A, and B are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.Type: GrantFiled: November 24, 2021Date of Patent: March 31, 2026Assignee: ELI LILLY AND COMPANYInventors: David Michael Hyman, Gregory Lawrence Lackner, Sheng-Bin Peng, Bree Leigh Richey, Chong Si
-
Publication number: 20250289830Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.Type: ApplicationFiled: May 29, 2025Publication date: September 18, 2025Inventors: David Anthony BARDA, Mario BARBERIS, Jolie Anne BASTIAN, Matthew Patrick BAUMGARTNER, Santiago CARBALLARES MARTIN, Kelly Wayne FURNESS, Pablo GARCIA LOSADA, Deqi GUO, Sonia Maria GUTIERREZ SANFELICIANO, James Robert HENRY, Richard Duane JOHNSTON, Jason Eric LAMAR, Tao LIU, Wenceslao LUMERAS AMADOR, Victoriano MOLERO FLÓREZ, Maria Lourdes PRIETO VALLEJO, Michael John RODRIGUEZ, Isabel ROJO, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammad Sadegh ZIA-EBRAHIMI
-
Publication number: 20250249019Abstract: The present disclosure provides method of treating a patient for cancer wherein one or more cells express KRas G12C mutant protein, comprising administering to a patient in need thereof, effective amounts of a compound of the formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A, B, and Y are as described herein, or pharmaceutically acceptable salts thereof, and an Aurora A inhibitor, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 6, 2023Publication date: August 7, 2025Inventors: Serge Louis BOULET, Xueqian GONG, Deqi GUO, David Michael HYMAN, Sheng-Bin PENG, Chong SI
-
Publication number: 20250228848Abstract: The present disclosure provides the compound of Formula I: or pharmaceutically acceptable salts thereof, methods and intermediates useful in preparing the compound of Formula I, pharmaceutical compositions containing the compound of Formula I, and methods of treating cancer using the compound of Formula I.Type: ApplicationFiled: April 7, 2023Publication date: July 17, 2025Inventors: Serge Louis BOULET, Lee Joseph BURNS, Kevin Paul COLE, Xueqian GONG, Deqi GUO, David Michael HYMAN, Michael Edward LAURILA, Ryan James LINDER, Sheng-Bin PENG, James Craig RUBLE, Chong SI, Hannah Leslie VONESH
-
Patent number: 12351591Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.Type: GrantFiled: March 24, 2023Date of Patent: July 8, 2025Assignee: ELI LILLY AND COMPANYInventors: David Anthony Barda, Jolie Anne Bastian, Kelly Wayne Furness, Deqi Guo, James Robert Henry, Richard Duane Johnston, Jason Eric Lamar, Tao Liu, Michael John Rodriguez, Almudena Rubio, Chong Si, Gaiying Zhao, Mohammad Sadegh Zia-Ebrahimi, Matthew Patrick Baumgartner, Isabel Rojo, Mario Barberis, Santiago Carballares Martin, Pablo Garcia Losada, Sonia Maria Gutierrez Sanfeliciano, Wenceslao Lumeras Amador, Victoriano Molero Florez, Maria Lourdes Prieto Vallejo
-
Publication number: 20240228511Abstract: The present invention provides compounds of the formula where R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y, and Z are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.Type: ApplicationFiled: June 8, 2022Publication date: July 11, 2024Inventors: David Anthony BARDA, Joshua Ryan CLAYTON, Jeffry Bernard FRANCISKOVICH, Kelly Wayne FURNESS, Douglas Linn GERNERT, James Robert HENRY, Richard Duane JOHNSTON, Spencer Brian JONES, Jason Eric LAMAR, Adam Marc LEVINSON, Curren Tapfuma MBOFANA, Michael John RODRIQUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammed Sadegh ZIA-EBRAHIMI
-
Publication number: 20240108618Abstract: Disclosed herein are dosing regimens for the administration of a compound of Formula I: or pharmaceutically acceptable salt thereof, or in combination with one or more of a second therapeutic agent, to a patient in need of such treatment.Type: ApplicationFiled: June 29, 2023Publication date: April 4, 2024Inventors: David Michael HYMAN, Xueqian GONG, Sheng-Bin PENG, Chong SI, Melinda Dale WILLARD
-
Publication number: 20240043451Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.Type: ApplicationFiled: March 24, 2023Publication date: February 8, 2024Inventors: David Anthony BARDA, Jolie Anne BASTIAN, Kelly Wayne FURNESS, Deqi GUO, James Robert HENRY, Richard Duane JOHNSTON, Jason Eric LAMAR, Tao LIU, Michael John RODRIGUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammad Sadegh ZIA-EBRAHIMI, Matthew Patrick BAUMGARTNER, Isabel ROJO, Mario BARBERIS, Santiago CARBALLARES MARTIN, Pablo GARCIA LOSADA, Sonia Maria GUTIERREZ SANFELICIANO, Wenceslao LUMERAS AMADOR, Victoriano MOLERO FLOREZ, Maria Lourdes PRIETO VALLEJO
-
Publication number: 20240025916Abstract: The present disclosure provides compounds of the formula: where R1, R2, R3, R4, R5, A, and B are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.Type: ApplicationFiled: November 24, 2021Publication date: January 25, 2024Inventors: David Michael HYMAN, Gregory Lawrence LACKNER, Sheng-Bin PENG, Bree Leigh RICHEY, Chong SI
-
Publication number: 20230339968Abstract: The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.Type: ApplicationFiled: June 28, 2023Publication date: October 26, 2023Inventors: Serge Louis BOULET, Kevin Charles FORTNER, Deqi GUO, David Michael HYMAN, Sheng-Bin PENG, Chong SI
-
Patent number: 11731984Abstract: The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.Type: GrantFiled: December 4, 2020Date of Patent: August 22, 2023Assignee: Eli LIlly and CompanyInventors: Serge Louis Boulet, Kevin Charles Fortner, Deqi Guo, David Michael Hyman, Sheng-Bin Peng, Chong Si
-
Publication number: 20210179633Abstract: The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.Type: ApplicationFiled: December 4, 2020Publication date: June 17, 2021Inventors: Serge Louis BOULET, Kevin Charles FORTNER, Deqi GUO, David Michael HYMAN, Sheng-Bin PENG, Chong SI
-
Patent number: 10202400Abstract: The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: and salts thereof, wherein R1, R2, R3, R4, n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.Type: GrantFiled: July 24, 2017Date of Patent: February 12, 2019Assignee: President and Fellows of Harvard CollegeInventors: Alec Nathanson Flyer, Hong Myung Lee, Andrew G. Myers, Cristina Montserrat Nieto-Oberhuber, Matthew D. Shair, Chong Si
-
Patent number: 9776992Abstract: 1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.Type: GrantFiled: November 24, 2015Date of Patent: October 3, 2017Assignee: Eli Lilly and CompanyInventors: Harold Burns Brooks, Robert Dean Dally, Timothy Barrett Durham, Kevin Robert Fales, Kwame Frimpong, Jefferson Ray McCowan, Frank George Njoroge, Timothy Alan Shepherd, Chong Si, Kenneth Jeff Thrasher, James Lee Toth, Zhipei Wu
-
Publication number: 20170233378Abstract: 1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.Type: ApplicationFiled: November 24, 2015Publication date: August 17, 2017Applicant: Eli Lilly and CompanyInventors: Harold Burns BROOKS, Robert Dean DALLY, Timothy Barrett DURHAM, Kevin Robert FALES, Kwame FRIMPONG, Jefferson Ray MCCOWAN, Frank George NJOROGE, Timothy Alan SHEPHERD, Chong SI, Kenneth Jeff THRASHER, James Lee TOTH, Zhipei WU
-
Patent number: 9714255Abstract: The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: and salts thereof, wherein R1, R2, R3, R4, n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.Type: GrantFiled: September 8, 2015Date of Patent: July 25, 2017Assignee: President and Fellows of Harvard CollegeInventors: Alec Nathanson Flyer, Hong Myung Lee, Andrew G. Myers, Cristina Montserrat Nieto-Oberhuber, Matthew D. Shair, Chong Si
-
Publication number: 20150376201Abstract: The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: and salts thereof, wherein R1, R2, R3, R4, n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.Type: ApplicationFiled: September 8, 2015Publication date: December 31, 2015Applicant: President and Fellows of Harvard CollegeInventors: Alec Nathanson Flyer, Hong Myung Lee, Andrew G. Myers, Cristina Montserrat Nieto-Oberhuber, Matthew D. Shair, Chong Si
-
Patent number: 9127019Abstract: The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: I and salts thereof, wherein R1, R2, R3, R4, n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.Type: GrantFiled: June 2, 2014Date of Patent: September 8, 2015Assignee: President and Fellows of Harvard CollegeInventors: Alec Nathanson Flyer, Hong Myung Lee, Andrew G. Myers, Cristina Montserrat Nieto-Oberhuber, Matthew D. Shair, Chong Si
-
Publication number: 20150111921Abstract: The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: I and salts thereof, wherein R1, R2, R3, R4, n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.Type: ApplicationFiled: June 2, 2014Publication date: April 23, 2015Applicant: President and Fellows of Harvard CollegeInventors: Alec Nathanson Flyer, Hong Myung Lee, Andrew G. Myers, Cristina Montserrat Nieto-Oberhuber, Matthew D. Shair, Chong Si
-
Publication number: 20110190323Abstract: The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: I and salts thereof, wherein R1, R2, R3, R4, n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.Type: ApplicationFiled: August 28, 2009Publication date: August 4, 2011Applicant: President and Fellows of Harvard CollegeInventors: Alec Nathanson Flyer, Hong Myung Lee, Andrew G. Myers, Cristina Montserrat Nieto-Oberhuber, Matthew D. Shair, Chong Si
